Scholarlink

Background <p>Neutral lipid storage disease with myopathy (NLSDM) is a rare genetic myopathy caused by mutations in the patatin-like phospholipase domain-containing protein (<i>PNPLA2</i>) gene. To date, the number of reported cases remains limited and the correlation between disease phenotypes and genotypes remains unclear.</p> Results <p>Our study presents eight NLSDM patients from a Chinese neuromuscular center, identifying two <i>PNPLA2</i> novel mutations through next-generation sequencing. Demographic and clinical data, as well as information from muscle electrophysiological, imaging, pathological, and genetic analyses, were collected. Several patients in the cohort were found to have right upper extremity weakness as the initial clinical manifestation. Notably, the first patient with facial muscle involvement was reported in this series. Muscle histopathology revealed a characteristic accumulation of lipid droplets predominantly in type 1 muscle fibers, featuring type 1 fiber atrophy concurrent with type 2 fiber hypertrophy, which was systematically described first in a summary manner.</p> Conclusions <p>This study prompted us to summarize abnormal clinicopathological features and explore the relationship between gene mutations and disease phenotypes in NLSDM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinicopathological-genetic features of neutral lipid storage disease with myopathy from a Chinese neuromuscular center

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Yi-Ning Luan,
  • Guan-Zhong Shi,
  • Qiu-Xiang Li,
  • Kun Huang,
  • Huan Yang

摘要

Background

Neutral lipid storage disease with myopathy (NLSDM) is a rare genetic myopathy caused by mutations in the patatin-like phospholipase domain-containing protein (PNPLA2) gene. To date, the number of reported cases remains limited and the correlation between disease phenotypes and genotypes remains unclear.

Results

Our study presents eight NLSDM patients from a Chinese neuromuscular center, identifying two PNPLA2 novel mutations through next-generation sequencing. Demographic and clinical data, as well as information from muscle electrophysiological, imaging, pathological, and genetic analyses, were collected. Several patients in the cohort were found to have right upper extremity weakness as the initial clinical manifestation. Notably, the first patient with facial muscle involvement was reported in this series. Muscle histopathology revealed a characteristic accumulation of lipid droplets predominantly in type 1 muscle fibers, featuring type 1 fiber atrophy concurrent with type 2 fiber hypertrophy, which was systematically described first in a summary manner.

Conclusions

This study prompted us to summarize abnormal clinicopathological features and explore the relationship between gene mutations and disease phenotypes in NLSDM.